Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Inclacumab was generally well tolerated in THRIVE-131
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Subscribe To Our Newsletter & Stay Updated